Trial Profile

MEDI4736 combinations in metastatic renal cell carcinoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Savolitinib (Primary) ; Tremelimumab (Primary)
Indications Renal cell carcinoma
Focus Adverse reactions; Therapeutic Use
Acronyms CALYPSO

Most Recent Events

04 Nov 2024 Status changed from active, no longer recruiting to completed.
24 Oct 2023 Results of updated 24-month efficacy analysis presented at the 48th European Society for Medical Oncology Congress.
18 Feb 2023 Results assessing relationship between MET, PD-L1 and TMB in these tumors and the relevance of other biomarkers including PIK3CA, PTEN and KRAS presented at the 2023 Genitourinary Cancers Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com